Lowers FY24 Adjusted Operating Expenses view $107.0M-$111.0M from $108.0M-$116.0M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRTX:
- Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
- Is HRTX a Buy, Before Earnings?
- Heron Therapeutics management to meet virtually with Needham
- Heron Therapeutics’ Zynrelef included in 2025 Non-Opioid Policy for Pain Relief
- Biotech Alert: Searches spiking for these stocks today